Press Release
Press Release
Press Contacts: Erik Cummins, Matt Hyams, Olivia Thomas
01.04.24
Pillsbury advised Vasa Therapeutics, Inc., a preclinical stage biopharmaceutical company developing novel therapies for cardiovascular aging, in a recent $6 million seed funding round led by Orphinic Scientific SA.
Private investments funds including NuFund Venture Group, SeedFolio, among others, also participated. Of the $6 million biotech investment, $2.3 million was supplemented by non-dilutive grant funding, according to a company press release.
Click here to learn more.
The Pillsbury deal team included Corporate partner Stan Lewandowski and associate Ann Kim.